Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor.

Content Provider	Europe PMC
Author	Kang, Min Kyu Lee, Heon Ju Choi, Joon Hyuk
Copyright Year	2019
Abstract	Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation of serum aminotransferase to clinically apparent acute hepatitis, which is associated with immunologic reactions. Imatinib-induced hepatotoxicity with autoimmune-like features can be treated by the discontinuation of imatinib mesylate and the administration of oral steroids. Here, we report a case of late-onset imatinib-induced hepatitis with autoimmune-like features in a patient with metastatic GIST, which was improved by oral corticosteroids.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6784631&blobtype=pdf
Journal	Yeungnam University Journal of Medicine [Yeungnam Univ J Med]
Volume Number	36
DOI	10.12701/yujm.2019.00115
PubMed Central reference number	PMC6784631
Issue Number	2
PubMed reference number	31620629
e-ISSN	23840293
Language	English
Publisher	Yeungnam University College of Medicine
Publisher Date	2019-01-21
Access Restriction	Open
Rights License	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2019 Yeungnam University College of Medicine
Subject Keyword	Corticosteroids Drug-induced liver injury Gastrointestinal stromal tumors Imatinib mesylate
Content Type	Text
Resource Type	Article
Subject	Medicine